Weight Loss Drug Biosimilar Global Market Report 2026

Weight loss drug biosimilars are biologic medications developed to closely replicate existing branded weight management biologic therapies in terms of safety, effectiveness, quality, and clinical outcomes after the expiration of the original product's patent or market exclusivity period. These drugs are produced using living cells and advanced biotechnology processes, often targeting metabolic pathways such as GLP-1 receptor activity to aid in obesity treatment and sustained weight management.

The primary reference drugs of weight loss drug biosimilar include semaglutide biosimilar, liraglutide biosimilar, and tirzepatide biosimilar. Semaglutide biosimilar refers to a biologically comparable version of semaglutide developed to deliver similar efficacy, safety, and therapeutic outcomes for weight management treatment. These products are available in injectable and oral formulations. They are used for applications such as weight loss in diabetic patients, weight loss in non-diabetic obese patients, and weight management in overweight individuals with comorbidities, with end users including hospitals and clinics, retail and online pharmacies, government health programs, and insurance-covered programs.

Tariffs are influencing the weight loss drug biosimilars market by increasing the cost of imported biologic raw materials, active pharmaceutical ingredients, and specialized manufacturing equipment required for complex biosimilar production. These rising costs are disrupting global supply chains, particularly affecting manufacturing-intensive regions in Asia-Pacific and export-dependent distribution networks serving North America and Europe. Injectable semaglutide, liraglutide, and tirzepatide biosimilar segments are the most affected due to their reliance on temperature-sensitive logistics and cross-border sourcing of high-precision components. In response, companies are localizing production, diversifying supplier networks, and investing in regional manufacturing hubs to reduce tariff exposure, while also creating opportunities for domestic biosimilar manufacturers to strengthen their market presence.

The weight loss drug biosimilar market research report is one of a series of new reports from The Business Research Company that provides weight loss drug biosimilar market statistics, including weight loss drug biosimilar industry global market size, regional shares, competitors with a weight loss drug biosimilar market share, detailed weight loss drug biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the weight loss drug biosimilar industry. This weight loss drug biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The weight loss drug biosimilar market size has grown exponentially in recent years. It will grow from $1.21 billion in 2025 to $1.53 billion in 2026 at a compound annual growth rate (CAGR) of 26.6%. The growth in the historic period can be attributed to dominance of branded glp-1 therapies, rising global obesity prevalence, limited biosimilar regulatory frameworks, high biologics production costs, strong physician preference for originator drugs.

The weight loss drug biosimilar market size is expected to see exponential growth in the next few years. It will grow to $3.88 billion in 2030 at a compound annual growth rate (CAGR) of 26.2%. The growth in the forecast period can be attributed to expiry of key biologic patents, expansion of biosimilar development pipelines, increasing healthcare cost containment policies, rising adoption in emerging markets, growth of long-term metabolic disease management programs. Major trends in the forecast period include GLP-1 biosimilar patent expiration driven market entry acceleration, intensifying price competition and biosimilar tendering in obesity therapeutics, expanding regulatory harmonization for biosimilar interchangeability approvals, growth of cold chain dependent biologics distribution networks for metabolic injectables, increasing payer and formulary driven access restrictions for branded weight loss biologics.

The increasing prevalence of obesity is anticipated to drive the growth of the weight loss drug biosimilar market in the coming years. Obesity is a medical condition marked by excessive accumulation of body fat, which elevates the risk of health complications such as diabetes, cardiovascular diseases, and hypertension. The growing number of obese and overweight individuals is mainly attributed to higher consumption of calorie-dense processed foods along with declining levels of physical activity. Weight loss drug biosimilars are used in obesity management by replicating approved anti-obesity biologic therapies that help regulate appetite, enhance satiety, and support metabolic regulation to promote weight reduction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government department, approximately 64.5% of adults in England were overweight or living with obesity in 2023-2024, increasing from 64.0% in 2022-2023, indicating a continued upward trend. Therefore, the increasing prevalence of obesity is contributing to the growth of the weight loss drug biosimilar market.

Major companies operating in the weight loss drug biosimilar market are focusing on improving access to affordable GLP-1-based therapies, expanding drug development collaborations, enhancing dosage and formulation options, and addressing the rising prevalence of obesity and lifestyle-related metabolic disorders through scalable and cost-efficient treatment solutions across emerging and developed markets. Affordable GLP-1-based therapies are treatments that use glucagon-like peptide-1 receptor agonists to manage conditions such as type 2 diabetes and obesity while ensuring greater financial accessibility for a wider patient population. For instance, in December 2024, Emcure Pharmaceuticals Limited, an India-based pharmaceutical company, launched Poviztra in India, representing its entry into the rapidly growing obesity and weight-management treatment segment. The injectable therapy, a once-weekly GLP-1 medication, was developed in partnership with Novo Nordisk, a Denmark-based healthcare company, and is positioned as a more affordable option compared with existing branded weight-loss medications. It is offered in multiple dosage strengths and is designed to support long-term weight management in combination with diet and lifestyle modifications. The launch enhances Emcure's footprint in cardiometabolic care and improves access to advanced obesity treatments in India, where demand for medical weight-management solutions is increasing rapidly due to growing lifestyle-related health challenges.

In April 2024, Biocon Biologics, an India-based biosimilars company, entered into a partnership with Biomm SA to commercialize semaglutide for the treatment of type 2 diabetes in Brazil. Under the agreement, Biocon will be responsible for the development, manufacturing, and supply of the drug, while Biomm will manage regulatory filings and oversee the product's launch and commercialization activities in Brazil. Biomm SA is a Brazil-based biotechnology and biopharmaceutical company.

Major companies operating in the weight loss drug biosimilar market report are Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Alvotech, Amgen Inc., Biocon Limited, Celltrion Inc., Cipla Limited, Dr. Reddy's Laboratories Limited, Emcure Pharmaceuticals Limited, Eris Lifesciences Limited, Glenmark Pharmaceuticals Limited, Hetero Labs Limited, Huadong Medicine, Jiuyuan Genetic Biopharmaceutical, Lupin Limited, Mankind Pharma, Oncosimis Biotech, Samsung Bioepis, Sandoz Group AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Limited, Viatris Inc., Wockhardt, Zydus Lifesciences Limited

North America was the dominating region in the weight loss drug biosimilar market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the weight loss drug biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the weight loss drug biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The weight loss drug biosimilars market consists of sales of semaglutide biosimilar injection, liraglutide biosimilar formulation, tirzepatide biosimilar candidate, exenatide biosimilar injection and amylin analog biosimilar. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Weight Loss Drug Biosimilar Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses weight loss drug biosimilar market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for weight loss drug biosimilar ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The weight loss drug biosimilar market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Reference Drug: Semaglutide Biosimilar; Liraglutide Biosimilar; Tirzepatide Biosimilar
• 2) By Formulation: Injectable; Oral
• 3) By Application: Weight Loss In Diabetic Patients; Weight Loss In Non Diabetic Obese Patients; Weight Management In Overweight Individuals With Comorbidities
• 4) By End User: Hospital And Clinic; Retail And Online Pharmacy; Government Health Programs; Insurance Covered Programs
• Subsegments:
• 1) By Semaglutide Biosimilar: Subcutaneous Injection; Oral Tablet; Long Acting Formulation; High Concentration Formulation
• 2) By Liraglutide Biosimilar: Subcutaneous Injection; Multi Dose Pen Injector; Pre Filled Syringe; Extended Stability Formulation
• 3) By Tirzepatide Biosimilar: Subcutaneous Injection; Single Dose Auto Injector; Multi Dose Pen Injector; High Strength Formulation
• Companies Mentioned: Alembic Pharmaceuticals Limited; Alkem Laboratories Limited; Alvotech; Amgen Inc.; Biocon Limited; Celltrion Inc.; Cipla Limited; Dr. Reddy's Laboratories Limited; Emcure Pharmaceuticals Limited; Eris Lifesciences Limited; Glenmark Pharmaceuticals Limited; Hetero Labs Limited; Huadong Medicine; Jiuyuan Genetic Biopharmaceutical; Lupin Limited; Mankind Pharma; Oncosimis Biotech; Samsung Bioepis; Sandoz Group AG; Sun Pharmaceutical Industries Limited; Teva Pharmaceutical Industries Ltd.; Torrent Pharmaceuticals Limited; Viatris Inc.; Wockhardt; Zydus Lifesciences Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.